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Many oncological drugs that are being used in the adjuvant setting were first submitted for
reimbursement in the metastatic stage, with differences in incremental cost-effectiveness
ratios (ICERs) in both settings having potential implications for reimbursement and pricing.
The aim of this study is to identify a possible trend in the cost-effectiveness for the early/
adjuvant and late/metastatic stages of oncological drugs through review and case study.
Methods
We reviewed pairs of cost-effectiveness analyses of the same oncological drug in different
stages for Scotland and the Netherlands. The case study in this report was directed at tras-
tuzumab in the Dutch situation. Using a simplified Markov model, the cost-effectiveness in
early and late stage of breast cancer was calculated and compared to the findings from the
review.
Results
Comparable studies were found for cetuximab, bortezomib and bosutinib. Treatments in the
late stage were found to be more expensive per QALY by a factor ranging from 1.5 to 12.
The case study provided a similar result; late stage treatment was more expensive by a fac-
tor 10. Using, for example, a threshold of €80,000/QALY, the early stage of cetuximab,
bosutinib and trastuzumab are deemed cost-effective, while their compared late stage is
lifted over the threshold and potentially considered not cost-effective.
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Conclusion
ICERs of oncological drugs used in different stages are more unfavourable in the late stage
than in the early stage. Applying a reasonable threshold may result in early stage treatment
being deemed cost-effective while late stage potentially not. Authorities should be aware of
this when assessing oncological drugs and interpreting the corresponding ICERs, in the sit-
uation where oncological drugs are generally most submitted for reimbursement in the late
stage initially.
Introduction
Cost-effectiveness is an increasingly important aspect in the reimbursement of new drugs, such
as oncological drugs. This class of drugs is sometimes viewed as relatively expensive and spe-
cific policies have been developed for their reimbursement, such as the “Policy Rule on Expen-
sive Drugs” in the Netherlands and “End-of-life drugs” exception from the cost-per-QALY
(quality-adjusted life year) threshold for the UK [1, 2]. Some of these drugs took decades to
develop, are highly innovative and require complex manufacturing processes, possibly and
potentially justifying relatively higher pricing. Depending on the country, there are further spe-
cial arrangements concerning these drugs, such as patient access schemes, price negotiations,
conditional reimbursement and agreements on volume being made by the pharmaceutical
industry, its cooperating partners and the government [3]. As said, one of the major issues in
the reimbursement is cost-effectiveness. Many countries, including the Netherlands, take cost-
effectiveness explicitly into consideration when evaluating reimbursement. Unlike for example
the UK, The Netherlands have no formal cost-per-QALY threshold although €80,000 is regu-
larly mentioned for drugs [4]. In the present situation, many oncological drugs that are being
used in the adjuvant setting are also registered for the metastatic phase, and cost-effectiveness
for reimbursement has been evaluated for both settings. This warrants for an interesting com-
parison of cost-effectiveness in both settings for the same drugs and questioning whether
trends over various drugs could be identified.
A priori, we postulated that as an overall trend cost-effectiveness would tend to be more
favorable in the early phase of the adjuvant setting than in the late phase of metastatic treat-
ment. The former might potentially be related to better utilities and higher efficacies, thus
benefiting a more positive cost-effectiveness outcome for the early phase. In addition, treat-
ment costs in the early stage could be lower, with potentially lower dosing being sufficient. Yet,
resource consumption could be again higher as the overall survival tends to be longer, prolong-
ing the duration of treatment for these patients. Ergo, an analytical approach is warranted to
substantiate our a-priori hypothesis. In this study, we make an effort to identify a consistent
trend in the cost-effectiveness of various specialist oncological drugs, in the adjuvant and meta-
static phases. The first part of the paper will be targeted to reviewing pairs of cost-effectiveness
analyses concerning the same oncological drug, but in different phases of illness; i.e., early vs.
late. In addition a model is created that specifically looks at trastuzumab as an example; i.e.,
the monoclonal antibody that targets against the extracellular domain of the (HER2)-positive
breast cancer patients, investigated in various clinical trials [5–7]. All in all, the aim of the inte-
grated study is to provide a possible trend in the cost-effectiveness for the early/adjuvant and
late/metastatic phases of oncological drugs.
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Methods
Review
For the review part of our paper, cost-effectiveness studies were searched on oncological
drugs used in different stages of cancer. Notably, pairs of comparable studies—one for
early stage and one for late stage—were searched for similar (or ideally the same) countries,
using a combination of search terms including [cost-effectiveness], [cancer], [oncology],
[treatment], [ICER] and [drug], excluding any non-pharmacoeconomic publications. No
time limitations were set; yet knowing that cost-effectiveness is only relevant in decision
making since the turn of the century, we would expect most analyses beyond approximately
2005. Countries addressed here involve the Netherlands and Scotland; with both countries
involved having relatively similar systems of reimbursement and clinical recommendations
[8]. To assess the cost-effectiveness, authorities in both countries only use phase III
clinical studies, as pharmacoeconomic evaluation is done at or soon after registration of
new drugs, typically in the absence of observational data. Other similarities concern: obliga-
tions for manufacturers to hand in cost-effectiveness analyses for new drugs, explicit roles
for cost-effectiveness studies in the process of recommendations, no formal threshold for
cost-effectiveness and publicly available information on these matters. Also, the Netherlands
and Scotland are comparably early with their drug assessments, whereas other countries
often review submissions later, with potentially data already being available for a cost-effec-
tiveness analysis. For example, in assessments of UK’s NICE, preferably observational data
are included.
Often the studies identified were performed for the specific purpose of reimbursement.
Studies were searched on the websites of the authorities involved [1, 9]; i.e.:
• Scottish Medicines Consortium (SMC); and
• The National Health Care Institute (“Zorginstituut Nederland” or ZiNL; former Dutch
Foundation for Health Care Insurance or “College voor Zorgverzekeringen” or CVZ) and its
Drugs Committee (“Commissie Geneesmiddelen”; former Committee Pharmaceutical Help
or “Commissie Farmaceutisch Hulp”).
Notably, for oncological drugs, these bodies sometimes apply slightly deviating and specific
methods, although the overall approach is grossly the same as for other types of drugs. For
example, the Dutch authorities had a specific policy rule in force for some time concerning
oncological (and other expensive) hospital drugs. Upfront, trastuzumab in early breast cancer
(HERA clinical trial [6]) and late breast cancer (M77001 study group [7]) and bortezomib in
multiple myeloma—with both early and late indications being analyzed by SMC [10,11]—were
seen as role models for our approach.
Searches on the authorities’ websites were done alphabetically. The economic evaluations
of both phases were compared to each other, with specific attention to the assumptions
concerning:
• Dosing and duration of treatment
• Efficacy and safety
• Costs
• Utilities underlying the QALYs; and
• Transition probabilities.
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Case study
A case study was included for illustrative purposes only and definitely not intended to provide
a full-fledged novel stand-alone analysis. The case study was directed at trastuzumab in the
Dutch situation. Trastuzumab is a monoclonal antibody that targets against the extracellular
domain of the (HER2)-positive breast cancer patients. A Markov model was developed to ana-
lyze the cost-effectiveness in adjuvant and metastatic stages. For both stages, situations with
trastuzumab were compared to standard-of-care (SOC). The model was based on the specific
trial data gathered in the adjuvant and metastatic phases [6, 7]. The costs and adjusted utilities
were taken from the report of the manufacturer of trastuzumab [12].
The Markov model, as shown in Fig 1, includes a hypothetical cohort of 1000 patients fol-
lowed in a lifetime simulation until the age of 100 years. For the early stage analysis, these 1000
patients start in the progression free (PF) stage, while in the late phase analysis these 1000
patients start in the progression (P) stage. The mean age of the patients was 51 years, corre-
sponding to a simulation of 49 years [6, 12].
For the early stage, data such as annual transition probabilities were based on Smith et al.
(2007), where trastuzumab’s effect on overall survival in Belgian patients with HER2+ breast can-
cer was investigated after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study
[6]. HERA is an international multicenter randomized trial that compared 1 year or 2 years of
trastuzumab treatment with observation alone after standard neoadjuvant or adjuvant chemo-
therapy in patients with HER2+ adjuvant breast cancer. Trastuzumab was administered every 3
weeks in a maintenance dose for 1 or 2 years. Results showed that the unadjusted hazard ratio
(HR) for the risk of death with trastuzumab compared with observation alone was 0.66. The risk
for disease-free survival was assumed at 0.64 in the trastuzumab group compared to the control
group. Results also showed that 1 year of treatment has a significant overall survival benefit after
a median follow-up of 2 years as compared to no trastuzumab. In accordance, in our case study,
patients were treated with trastuzumab during the first year modeled. Transition probabilities
from PF to P used in the HERA study were directly taken into our case study [6], whereas for the
transition probability from PF to death (D), data from the Dutch Central Bureau of Statistics
(CBS) was used. Mortality transition probabilities were based on the assumption that the proba-
bilities to die during PF equal general mortality rates for women in the same age classes [13].
For the late stage, data such as annual transition probabilities were based on Marty et al.
(2005), where first line treatment of trastuzumab plus docetaxel was compared to docetaxel
alone in patients with HER2+ metastatic breast cancer [7]. In this specific study, patients were
randomly assigned to six cycles of docetaxel every 3 weeks, with or without trastuzumab until
disease progression. Results showed that trastuzumab plus docetaxel was significantly superior
to docetaxel alone in terms of overall response rate (61% v 34%), overall survival (median at
31.2 v 22.7 months), time to disease progression (median at 11.7 v 6.1 months), time to treat-
ment failure (median at 9.8 v 5.3 months) and duration of response (median at 11.7 v 5.7
months), with marginal additional toxicity. In the late stage of our case study, patients were
assumed to be treated until death [7]
In the Markov model, transition probabilities were used for early and late stage trastuzumab
treatment and SOC. In both stages, trastuzumab was assigned a positive effect on health, as transi-
tion probabilities from PF to P are lower in the trastuzumab group compared to SOC. The transi-
tion probability from P to D also decreases when adding trastuzumab to the treatment regimen.
In the case study, all costs were based on the Dutch treatment guideline for trastuzumab
[12]. For the adjuvant stage, patients receiving trastuzumab were assumed having a 3-weeks
regimen after finishing the adjuvant chemotherapy. CVZ assumed an average Dutch treatment
period of 39 weeks with 6.67mg/kg for the adjuvant stage, resulting in a cumulative dosage of
Comparing ICERs in Early versus Late Stage Cancer
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trastuzumab after 13 administrations of 5522 mg [12]. With a price of €706 inclusive VAT per
150 mg [12], total costs for one year of trastuzumab treatment result at €26,000. Trastuzumab
is injected intravenously in the hospital. According to the manufacturer, administration costs
are €4090 for one year [11]. Trastuzumab is known for cardiac toxicity, so heart monitoring
was assumed necessary [12]. The total costs in this respect are €1120, according to the manu-
facturer [12]. For the metastatic phase the average survival rate of 31 months amounted to
drug costs of €10,400 based on a weekly dosage at 2.67mg/kg of bodyweight.
According to the CVZ report, adjuvant related health state costs were assumed at €5230 per
year for the progression-free state. Metastatic health state costs were assumed at €55,800 for
the first year and €12,800 for the second year, the difference being based on stopping the treat-
ment [12]. Docetaxel costs would merely cancel each other out when comparing the groups
with and without trastuzumab, therefore they are not taken into account. For simplicity, meta-
static health state costs were calculated based on the survival rate and accompanying monthly
costs, resulting in metastatic health state costs of (12 months x €4.650 + 19 months x €1067/
3112 =) €29,500 per year. Table 1 shows a comprehensive overview of the data used for the
illustrative case study of trastuzumab in early and late stage treatment.
Effects, measured in QALYs gained, and costs used were discounted according to the Dutch
guidelines: 1.5% per year for QALYs and 4% per year for costs [11]. All (incremental) costs in this
study were adjusted for inflation to 2014 prices [14]. All in all, except with some slight fine tun-
ings and updates, we basically recreated the manufacturer’s submission to the Dutch CVZ (cur-
rently ZiNL) after 4 years (t = 4) of conditional reimbursement with evidence development [12].
Results
Review
An overview of the drugs identified and their corresponding ICERs for early and late stages are
reported in Table 2, with all ICERs being expressed in 2014 price levels. Only few consistent
pairs of assessments could actually be found.
Fig 1. The Markovmodel with transition probabilities. PF: Progression-free survival, P: Progression, D:
Death, PF-> P: Progression-free to progression, PF-> D: Progression-free to death, P->D: Progression to
death.
doi:10.1371/journal.pone.0146551.g001
Comparing ICERs in Early versus Late Stage Cancer
PLOS ONE | DOI:10.1371/journal.pone.0146551 January 22, 2016 5 / 12
Cetuximab
Cetuximab is a monoclonal antibody, which has been approved for use with concomitant
radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN). A study for the SMC analyzed cost-utility for the adjuvant phase using a statistical
“cure”model based on a phase 3, open-label randomized controlled trial [15] to estimate vari-
ous survival rates and costs [16]. The comparison made involved cetuximab and radiotherapy
versus radiotherapy alone. Incremental cost-effectiveness was €11,100/QALY at 0.94 QALY’s
gained per patient treated with cetuximab. For the Netherlands, CVZ had assessed the dossier
submitted by the manufacturer on cetuximab for that same indication [17]. Based on a very
similar model being applied for Scotland, estimated cost-effectiveness for the Dutch situation
was €12,000/QALY at 1.08 QALYs per patient gained treated with cetuximab; i.e., fully in line
with the estimates for the SMC.
Similarly, CVZ assessed the submitted file for cetuximab in the metastatic phase for the
Dutch setting [18]. Notably, the exact indication investigated referred to metastatic and/or
recurrent SCCHN. The Markov model developed was based on the EXTREME clinical trial
[19], inclusive mapping of EORTC scores in the trial on utilities. The comparison analyzed
involved cisplatin or carboplatin and fluorouracil (C/C&F) and cetuximab versus C/C&F only.
Incremental cost-effectiveness was €151,000/QALY at 0.14 QALYs gained per patient treated
with cetuximab. Compared to early stage, the late stage ICER is a factor 12 higher.
Bortezomib
Bortezomib is a proteasome inhibitor and is used to treat multiple myeloma. A cost-utility
analysis was done for the SMC on data from the phase 3 PETHEMA/GEM trial, comparing
bortezomib + standard treatment to standard treatment of thalidomide + dexamethason in
Table 1. Overview of parameters in early and late stage HER2+ breast cancer treatment with trastuzumab.
Aspect Early stage Late stage
Patient population HER2+ breast cancer HER2+ metastatic breast cancer
Comparator Observation alone Docetaxel
Cycles Administered every 3 weeks for1 or 2 years Six cycles of trastuzumab + docetaxel or





-Trastuzumab treatment €26,000 €10,400
-Heart monitoring €1,120 €1,120
-Health state costs €5,230 €29,500
Transition Probability Early Trastuzumab Early SOC Late Trastuzumab Late SOC
PF! P 0.0999 0.1357 - -
P! D 0.716 0.727 0.2306 0.2952
PF! D Age-dependent Age-dependent - -
PF 0.8978 0.862 - -
P 0.284 0.273 0.7694 0.7048
PF: Progression-free survival, P: Progression, D: Death, PF-> P: Progression-free to progression, PF-> D: Progression-free to death, P->D: Progression to
death.
doi:10.1371/journal.pone.0146551.t001
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early multiple myeloma [10]. A Markov model was developed with 3 health states, and QALYs
and costs based on the literature. Notably, the incremental effects were 1.04 QALYs per patient,
with corresponding incremental costs at €28,750. This resulted in an ICER of €27,600/QALY.
The sensitivity analyses showed that the ICER varied between €23,000 and €38,200 when
mortality probabilities were changed by +/- 20%. Other variables, such as the time-horizon
chosen and an alternative post-stem cell transplantation survival resulted in ICERs of €33,500
and €24,000, respectively. Ergo, ICERs were quite robust for bortezomib in early multiple
myeloma.
Bortezomib can alternatively be used as monotherapy in the treatment of progressive meta-
static multiple myeloma in patients who already had previous therapy and/or bone marrow
transplantation. In a study for the SMC, bortezomib monotherapy was compared to high-dose
of dexamethason in patients in this late stage multiple myeloma in patients who already experi-
enced a first relapse [11]. Data from the bortezomib registration trial was complemented with
literature to design the Markov model. The incremental effects were 0.64 QALYs per patient,
while incremental costs were €27,700. This resulted in an ICER of €43,100/QALY. Sensitivity
analysis showed that in 32% of all cases the ICER was<€42,500/QALY. According to the
underlying clinical trial, some patients needed more than the standard 24 doses of bortezomib,
but that did not increase the ICER significantly. Similarly, CVZ compared bortezomib to tha-
lidomide + dexamethason in a similar patient population [20]. The incremental effects were
Table 2. Overview of ICERs for the adjuvant andmetastatic phases (€ per QALY; price levels: 2014); sources: SMC and CVZ/ZiNL.
Aspect Cetuximab Bortezomib Bosutinib
Indication
-Early Locally advanced squamous
cell cancer of the head and
neck






squamous cell cancer of the
head and neck
Monotherapy for the treatment of progressive multiple
myeloma in patients who have received at least one prior
therapy and who have already undergone or are unsuitable
for bone marrow transplantation
Treatment of adult
patients with blast phase
Ph+ CML
Comparator
-Early RT + Cetuximab vs RT Bortezomib+TD vs TD Bosutinib vs H/SCT
-Late C/C&F+cetuximab vs C/C&F Bortezomib vs dexamethosone Bosutinib vs H/SCT
Incremental costs
Early €10,400-€12,900 €28,750 €125.000
Late €21,100 €27,700 €44.800
Incremental QALYs
Early 0.94–1.08 1.04 3.6–4.8
Late 0.14 0.64–0.7 0.6
ICER (€/QALY)
Early €11,100**-€12,000* €27,600** €26,200**-€34,700**
Late €151,000* €39,900*-€43,300** €72,900**
Potential explaining factor
for difference in early vs
late ICER
Higher costs and lower
QALYs in late stage
Lower QALYs in late stage Bigger difference between




RT = RadioTherapy; TD = thalidomide and dexamethasone; H = Hydroxicarbamide; SCT = Stem cell transplantation; Ph+-CML = Philadelphia
chromosome positive chronic myelogenous leukaemia; C/C&F = cisplatin or carboplatin and ﬂuorouracil.
doi:10.1371/journal.pone.0146551.t002
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0.7 QALYs per patient, while incremental costs were €27,800. This resulted in an ICER of
€39,900/QALY, which is similar to results from SMC. Compared to early stage, the late stage
ICER is a factor 1.5 higher.
Bosutinib
A study for the SMC focused on the cost-utility of bosutinib for Philadelphia-chromosome
positive chronic myeloid leukemia (Ph+ CML), in chronic acceleration and the blast phases of
the disease [21]. Notably, the amount of affected red blood cells increases with every phase,
with the chronic phases considered here as adjuvant or early stage and blast as metastatic or
late phase. In the study, bosutinib is compared to hydroxycarbamine and stem cell transplanta-
tion in adult patients who were previously treated with one or more tyrosin kinase inhibitors
and who were not eligible for treatment with imatinib, nilotinib and dasatinib. Markov model-
ing was used, utilities were derived from the National Institute of health and Clinical Excellence
(NICE) study on imatinib and costs were also based on NICE-analyses.
In the early stage, incremental costs varied from savings (stem cell) to approximately
€125,000 per patient and QALYs from 3.6 to 4.8. In the late stage, these numbers were up to
approximately €44,800 and to 0.6, respectively. In the end, cost-effectiveness ratios were far
higher in the late than in the early stage; i.e. up to over €72,900/QALY versus cost saving poten-
tials. This resulted in the late stage ICER being at least a factor 3 higher than early stage.
Case study trastuzumab
As mentioned, we basically recreated the manufacturer’s submission for trastuzumab at t = 4
for the Netherlands [12]. Trastuzumab lowers all transition probabilities in both early and late
stage, making it an effective treatment for HER2-positive breast cancer. Compared to late
stage, the early stage treatment lowers the probability to transition to next state more, making
it relatively more effective. The highest costs and lowest health gains were both found after
treating patients with trastuzumab in late stage.
After discounting, early stage incremental costs were €25,000 with 2.7 QALYs gained per
patient, resulting in an ICER of €9,250/QALY. Late stage incremental costs were €123,000 with
1.3 QALYs gained per patient, resulting in an ICER of €94,600/QALY. For example, using a
potential threshold of €80,000/QALY [4], the early stage would be deemed cost-effective, while
the late stage is a factor 10 more expensive, lifting it over the assumed threshold and potentially
considered not cost-effective.
Discussion
We searched for analyses performed by one and the same authority for oncological drugs in
the early and late stages of disease, but these are still rare. Exactly these studies could produce
reliable connections between both stages. Still, scarce studies that were found, often slightly dif-
fered in patient population, clinical data, perspective, costs, discounting utilities, frequencies of
treatment and parameters of survival. Sometimes CVZ or SMC offered only early or late stage
cost-utility analyses. In that case, in addition to using SMC and CVZ as sources, additional lit-
erature was identified in PUBMED and subsequently [22], ideally for the same or comparable
countries.
Treatments in the late stage were found to be more expensive by a factor ranging from 1.5
to 12. Notably, at a potential threshold of €80,000/QALY [4], cetuximab and bosutinib can be
considered cost-effective in the early stage, while late-stage ICERs may be considered not cost-
effective. Relatively low ICERs in the early stage are caused by a major potential still to gain
QALYs and relatively low medical costs, as patients are still relatively healthy and a likelihood
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for cure still exists. Subsequently, a high ICER in the late phase may be related to a lower poten-
tial to win QALYs, as overall survival is relatively short in the late stage. Furthermore, costs in
the metastatic phase are often higher, as more frequent use of health care is usually needed to
treat metastatic patients. Our results illustrate that in early stage, QALYs gained range from
0.94 to 4.8 QALYs, while in late stage QALYs gained ranged from 0.14 to 0.7. Also, in early
stage, incremental costs ranged from €11,100 to €125,000, while in late stage incremental costs
ranged from €44,800 to €1,079,000. It should be noted that all adjuvant trials used for the cost-
effectiveness analyses are based on a relatively short follow-up time of 1–3 years. Therefore it
seems possible that hazard ratios could be lower after a longer period of time, which could
impact the ICER negatively.
Bortezomib could be considered cost-effective in both early and late stage. In most cases,
costs for metastatic patients are much higher compared to adjuvant patients, as more intensive
(and expensive) therapy is needed. Bortezomib is the exception, as previously untreated adju-
vant patients get 4 cycles of therapy, while the metastatic patients, who presumably already had
their progressive myeloma treated, get “only” 2 cycles of therapy [10, 11]. The late phase ICER
(€43,100) is still higher than in the early phase (€27,770), because there are less QALYs to be
gained in the late phase (0.64 vs 1.04). Also, additional costs like GP visits and extra controls
drove the metastatic costs further up, resulting in a higher ICER. In addition, a study for NICE
for metastatic patients receiving 3 cycles of therapy resulted in €53,600/QALY [23], very simi-
lar to the SMC study.
In addition, for cetuximab a published study was identified that specifies cost-utility for Bel-
gium and the UK in early; i.e., the adjuvant phase [24]. Notably, the comparison made involved
cetuximab and radiotherapy versus radiotherapy alone. Local costs were used in both countries,
whereas a uniform discount rate at 3.5% was applied. The incremental effects were 1.08 QALYs
for Belgium and the UK, while incremental costs were €11,400 and €12,900, respectively. Treat-
ment with cetuximab plus radiotherapy won 3.96 QALYs on average, compared to 2.88
QALYs when treating with radiotherapy only. Treatment with cetuximab was grossly €10,000
more expensive than radiotherapy alone, with similar patterns for both countries. Similarly,
NICE did the same study on cetuximab in the early stage, resulting in an ICER of €10,200/
QALY [25], which is similar to the previously found ICER of €11,100/QALY [16].
Furthermore, a Canadian study looked at the cost-effectiveness of cetuximab + platinum-
based chemotherapy of patients with recurring or metastasized SCCHN in the primary care
[26]. Data was taken from a phase 3 trial on patients with SCCHN. Using a Markov model, var-
iables as costs, side effects, QALY’s etc were taken in to account when comparing the effects of
cetuximab + standard with only the standard treatment. Gaps in the phase 3 trial were filled
with information from the manufacturer or literature. The discount rate was 5% for effects and
costs. The assumption was made that cetuximab did not influence the quality of life in any
way. The incremental effects were 0.093 QALY’s, while incremental costs were €28,300. This
resulted in an ICER of €303,000/QALY. A sensitivity analysis showed that the ICER is most
sensitive to the cetuximab price and the risk of progression. It also showed that the model is
not sensitive for a change in the severity of side effects, its frequencies and their subsequent
costs. The ICER remained above €215,000. Similarly, NICE did a study on cetuximab in the
late stage, resulting in an ICER of €155,000/QALY [27].
CVZ analyzed trastuzumab according to the HERA trial in early stage breast cancer for the
Dutch situation, resulting in an ICER of €16,700/QALY, very similar to our case study’s early
stage estimate [12]. For late stage trastuzumab treatment, a Norwegian cost-effectiveness analy-
sis by Marty et al. (2005) resulted in incremental costs of €54,952 and ICERs ranging from
€78,500 to €183,200 per life-year gained, adding between 0.3 and 0.7 years [28]. Only effects
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were discounted with 5%, as all costs occurred in the first year. This is on par with the late stage
ICER from our case study of €94,600/QALY, at 1.3 QALYs gained per patient.
Notably, more favorable transition probabilities, lower treatment costs and more QALYs
saved are factors that contribute to a more favorable ICER in use of drugs in early stage oncol-
ogy. For reimbursement agencies, this potential trend in early vs late stage cost-effectiveness
could mean that ICERs in the late stage should be considered taking into account the anticipa-
tion that ICERs tend to be lower after the same oncological drug is submitted later on for early
stage treatment. Pharmaceutical companies could anticipate accordingly by looking at different
price/volume situations and patient access schemes.
From our case study, trastuzumab treatment would be cost-effective only in the early stage
using a threshold of €80,000/QALY. Late stage cost-effectiveness is a factor 10 more unfavour-
able than early stage. By definition, this is related to differences in incremental costs and
QALYs gained between early and late stage. The case study resulted in lower incremental costs
for early stage (€25,000 vs €123,000 in late stage), with lower progression-free health state costs
being the most influential factor. Also, more QALYs gained (2.7 vs 1.3 in late phase) contrib-
uted to the early-stage treatment being considered cost-effective, while late-stage treatment is
not.
Another potential factor for differences in ICERs relates to transition probabilities. Early
stage treatment lowers the transition probability to progress by 26%. The comparable late stage
transition probability to death decreases by 22%, rendering trastuzumab treatment more effec-
tive in the early stage compared to late stage. This further explains why early treatment is more
cost-effective than late stage treatment. We note that one limitation in our case study is that in
the early stage trastuzumab is considered alone, while in the late stage, trastuzumab+docetaxel
is considered.
In general, using for example a threshold of €80,000/QALY [4], early stage treatment may
often be considered cost-effective while late stage is often not. Authorities should be aware of
this when assessing oncological drugs and interpreting the corresponding cost-effectiveness
ratios. Even though a pattern is identified in our study, further research is needed to keep con-
firming our findings.
Conclusions
Through review and case study, we found that the ICERs of drugs used in different stages of
cancer, are higher (i.e. more unfavorable) in the metastatic phase than in the adjuvant phase or
early vs. late stages. Reasons identified were higher costs because of a more intensive treatment,
more drug use and subsequently more intensive monitoring in the late stages of cancer. More-
over, in the early stages of cancer, a higher potential for QALY gains exist, compared to the
metastatic phase. Notably, compared to early-stage ICERs, late-stage ICERs were found to be
1.5 to 12 times higher. Our case study on trastuzumab further confirmed our findings.
Ergo, oncological drugs in the respective stages of early and late cancer may hugely differen-
tiate in the respective ICERs. Authorities often first-time encounter with the late-stage indica-
tion of these drugs, with relatively unfavourable ICERs. Not always may they sufficiently
differentiate between early and late stages in their interpretation of results and not envision the
future more cost-effective application of the same drug in the early stage. Notably, an approval
in the early setting frequently leads to a shift in use of the drug from the late to the early setting
rather than that the drug is being used in both settings. Such future outlooks illustrate that
exact differentiation between both stages is crucial and may help authorities to better allocate
scarce resources in oncology and enhance access to patients to these potentially life-savings
drugs.
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